Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the persistent positivity of at least one antiphospholipid antibody (aPL), along with clinical manifestations defined in the 2023 ACR/EULAR classification criteria (5). This evidence concerns the gene FASLG and antiphospholipid syndrome.